JUNS Stock — Jupiter Neurosciences, Inc. Common Stock

Jupiter Neurosciences, Inc. Common Stock (JUNS)

Updated October 16, 2026.

JUNS is a Stock. Total return is -99.3% over the past 1.9 years, 128.6 points behind SPY at 29.3%.

Jupiter Neurosciences is a clinical-stage pharmaceutical company developing therapeutics for central nervous system disorders and rare diseases, with drug candidates in Phase II trials for conditions including Parkinson's disease, Alzheimer's disease, and rare metabolic disorders; the company also commercializes nutritional supplements for skin, mental clarity, and fitness under the Nugevia brand. The company does not currently distribute to shareholders. This security may appeal to investors with high risk tolerance seeking exposure to early-stage drug development, though it carries substantial clinical and commercial uncertainty typical of pre-revenue pharmaceutical companies.

JUNS performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.3% over the past 1.9 years, 128.6 points behind SPY at 29.3%. Over the past year its total return — price change plus distributions reinvested — is -97.6%. Its deepest 1-year drawdown was 98.1%.

JUNS key facts

Asset type

Stock

Asset class

Equity

Inception date

12/03/2024

Distribution frequency

None

Last close

$2.90 (as of 2026-10-16)

Market cap

$3,830,304

Average volume

13900.0

Payout ratio

0.0%

Forward P/E

28.6533

EPS

$-18.94

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

JUNS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 98.1%.

Who may consider JUNS — and who may not

It is a weaker fit for investors who need monthly cash flow (JUNS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on JUNS

• All tickers starting with J

Tagged: Healthcare.

Frequently asked questions